Phase 2
Completed N=229
CO Monitoring for Tobacco Cessation in Quitlines
Source: ClinicalTrials.gov NCT05327660 ↗Enrolled (actual)
229
Serious AEs
0.0%
Results posted
Oct 2024
Primary outcomePrimary: Treatment Satisfaction — 38; 44; 56 Participants
Summary
The present study is a 3-arm randomized controlled pilot study. Participants who call the Maryland Tobacco Quitline and are eligible for study participation are randomized to receive quitline tobacco cessation treatment as usual (TAU), TAU plus remote carbon monoxide (CO) monitoring via smartphone app, or TAU plus remote carbon monoxide monitoring plus incentives vis smartphone app. The investigators hypothesize that remote CO monitoring will be feasible and acceptable to deliver in the quitline setting, will increase treatment engagement, and will increase tobacco cessation and treatment satisfaction rates.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Treatment Satisfaction |
38; 44; 56 | — |
| PRIMARY Treatment Engagement |
2.2; 2.3; 2.7 | — |
| PRIMARY Self-reported Tobacco Abstinence |
15; 18; 25 | — |
| SECONDARY Biochemically Verified Tobacco Abstinence |
6; 14; 20 | — |
| SECONDARY Engagement With CO Monitor |
7.7; 54.8; 80.9 | — |
| SECONDARY Satisfaction With CO Monitor |
30; 38; 51 | — |
Eligibility Criteria
Inclusion Criteria
- Daily cigarette smokers calling into participating quitlines
- 18 year or older
- Reads and speaks English
- Has a smartphone with a data plan
- Willing to download and use study app
- Willing to use CO monitor
Exclusion Criteria
- Pregnant or breast feeding
Data sourced from ClinicalTrials.gov (NCT05327660). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.